Influence of famotidine on verapamil pharmacokinetics in rats

被引:0
作者
Kamal M. Matar
机构
[1] Kuwait University,Department of Applied Therapeutics, Faculty of Pharmacy
来源
European Journal of Drug Metabolism and Pharmacokinetics | 2005年 / 30卷
关键词
Verapamil; Famotidine; Pharmacokinetics; Interaction; Rats;
D O I
暂无
中图分类号
学科分类号
摘要
The effect of famotidine (4 mg/kg, p.o.) on the kinetic profile of co-administered verapamil (20 mg.kg1, p.o.) was studied in the rat. Plasma verapamil levels were collected serially for 12 h and measured using sensitive HPLC method. The pharmacokinetic parameters (elimination half-life, area under the plasma concentration-time curve, peak plasma levels and the times to attain these plasma levels) of verapamil were evaluated in the rat. The results indicate that co-administered famotidine did not significantly alter the pharmacokinetic profile of verapamil in the rat. The present finding suggests that famotidine may safely be co-administered with verapamil but clearly further studies in human subjects are needed to reliably rule out the potential interaction of these two drugs.
引用
收藏
页码:219 / 222
页数:3
相关论文
共 101 条
[1]  
Klein H.(1986)Digitalis and verapamil in atrial fibrillation and flutter. Is verapamil now the preferred agent? Drugs 31 185-97
[2]  
Kaplinsky E.(2000)Gender-specific effects of verapamil pharmacokinetics and pharmacodynamics in humans J. Clin. Pharmacol. 40 219-230
[3]  
Krecic-Shepard M.(1976)Physiological disposition of verapamil in man Cardiovasc. Res. 10 605-612
[4]  
Barnas C.(1978)Verapamil: a review of its pharmacological properties and therapeutic use Drugs 15 169-197
[5]  
Slimko J.(1982)The pharmacology of verapamil. IV. Kinetic and dynamic effects after a single intravenous and oral doses Clin. Pharmacol .Ther. 31 418-426
[6]  
Jones M.(1986)Clinical pharmacokinetics of verapamil, nifedipine and diltiazem Clin. Pharmacokinet. 11 425-449
[7]  
Schwartz J.(1999)Role of P-glycoprotein-mediated secretion in absorptive drug permeability: an approach using passive membrane permeability and affinity to P-glycoprotein J. Pharm. Sci. 88 1067-1072
[8]  
Schomerus M.(1993)Pharmacology of gastric acid inhibition Baillieres Clin. Gastroenterol. 7 23-54
[9]  
Spiegelhalder B.(1994)Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers Ther. Drug Monit. 16 444-449
[10]  
Stieren B.(1987)Pharmacokinetics of famotidine in man Int. J. Clin. Pharmacol. Ther. Toxicol. 25 458-463